Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
ION363, the first medicine to specifically target FUS-ALS, is among Ionis' wholly owned assets the company plans to commercialize ALS portfolio now includes four clinical-stage investigational antisense medicines designed to treat the root causes of gen... Biopharmaceuticals, Neurology Ionis Pharmaceuticals, amyotrophic lateral sclerosis, FUS-ALS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2021 Category: Pharmaceuticals Source Type: news

Helixmith Announces First Patient Enrolled in Phase 2 Study of...
Helixmith announced today enrollment of the first patient in a new Phase 2A clinical trial, REViVALS-1A, targeting Amyotrophic Lateral Sclerosis (ALS) using Helixmith’s flagship gene therapy product...(PRWeb March 10, 2021)Read the full story at https://www.prweb.com/releases/helixmith_announces_first_patient_enrolled_in_phase_2_study_of_engensis_vm202_for_amyotrophic_lateral_sclerosis/prweb17786005.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 10, 2021 Category: Pharmaceuticals Source Type: news

Researchers reveal process behind harmful glial cell change in motor neurone disease
(The Francis Crick Institute) Scientists at the Francis Crick Institute and UCL have identified the trigger of a key cellular change in amyotrophic lateral sclerosis (ALS), a type of motor neurone disease. The findings could help develop new treatments for many neurological diseases with the same change, including Parkinson's and Alzheimer's. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 3, 2021 Category: Biology Source Type: news

ALS neuron damage reversed with new compound
(Northwestern University) Scientists have identified the first compound that eliminates the ongoing degeneration of upper motor neurons that become diseased and are a key contributor to ALS (amyotrophic lateral sclerosis), a swift and fatal neurodegenerative disease that paralyzes its victims. In ALS, movement-initiating nerve cells in the brain and muscle-controlling nerve cells in the spinal cord die. After administering the new compound,, the diseased brain neurons stopped degenerating so much that they became similar to healthy control neurons after 60 days of treatment. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 23, 2021 Category: International Medicine & Public Health Source Type: news

Researchers find evidence of protein folding at site of intracellular droplets
(University of Notre Dame) Researchers at the University of Notre Dame found that elevated concentrations of proteins within the droplets triggered a folding event, increasing the potential for protein aggregation -- or misfolding -- which has been linked to neurological diseases including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2021 Category: International Medicine & Public Health Source Type: news

Bringing innovation to rare disease patients in Europe
Why is Biogen focusing on rare diseases?  About 6,000 different rare diseases have been identified to date and these are estimated to affect 30 million people across Europe. It is essential that we collaborate across the medical community, industry, and governments to develop new therapies, explore new technologies and ensure equitable access to treatment. We must innovate across every aspect of treatment to transform the lives of people in these underserved communities.  At Biogen, we have shown that pioneering in neuroscience can change the course of treatment for certain rare diseases. We have transformed the ...
Source: EyeForPharma - February 17, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
For many of the 30 million people affected by rare disease in the EU, lack of effective treatments and discrepancies in access and diagnosis are still common issues. Strong political will, innovation and further cooperation between countries remain vital to improve outcomes and transform their quality of life.To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021.Andrea Corazza, Head of Brussels Liaison Office, Public Policy& Government Affairs, Biogen, says: “With this campaign, we want to help put...
Source: EyeForPharma - February 11, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Occupational therapy interventions in adults with multiple sclerosis or amyotrophic lateral sclerosis: a scoping review - De-Bernardi-Ojuel L, Torres-Collado L, Garc ía-de-la-Hera M.
This scoping review aims to describe occupational therapy interventions carried out with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) patients in occupational therapy. A peer review of the literature was conducted in different databases:... (Source: SafetyLit)
Source: SafetyLit - February 8, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

The Microglial Component of Amyotrophic Lateral Sclerosis The Microglial Component of Amyotrophic Lateral Sclerosis
The authors explore evidence for the contribution of microglia to neurotoxicity and neuroprotection in amyotrophic lateral sclerosis. Might elucidation of these processes lead to novel therapeutics?Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Poor corticospinal motor neuron health is associated with increased symptom severity in the acute phase following repetitive mild TBI and predicts early ALS onset in genetically predisposed rodents - Alkaslasi MR, Cho NE, Dhillon NK, Shelest O, Haro-Lopez PS, Linaval NT, Ghoulian J, Yang AR, Vit JP, Avalos P, Ley EJ, Thomsen GM.
Traumatic brain injury (TBI) is a well-established risk factor for several neurodegenerative disorders including Alzheimer's disease and Parkinson's disease, however, a link between TBI and amyotrophic lateral sclerosis (ALS) has not been clearly elucidate... (Source: SafetyLit)
Source: SafetyLit - February 6, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Imaging zebrafish movements in 3D to better understand ALS disease
(Institut national de la recherche scientifique - INRS) An interdisciplinary team of the Institut national de la recherche scientifique (INRS) used an innovative imaging technique for a better understanding of motor deficits in Amyotrophic Lateral Sclerosis (ALS). The researchers were able to follow the escape behaviour of normal and disease zebrafish models, in 3D. Their results have recently been published inOptica, the flagship journal of the Optical Society (OSA). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 29, 2021 Category: International Medicine & Public Health Source Type: news

Suicide among veterans with amyotrophic lateral sclerosis - Lund EM, Hostetter TA, Forster JE, Hoffmire CA, Stearns-Yoder KA, Brenner LA, Sohi MT.
INTRODUCTION: The purpose of this study was to estimate the risk of death by suicide for those with amyotrophic lateral sclerosis (ALS) seeking care within the Veteran Health Administration (VHA). METHODS: This was a retrospective, cohort study. Ex... (Source: SafetyLit)
Source: SafetyLit - January 25, 2021 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

New molecular structures associated with ALS
(University of Seville) Researchers from the University of Seville and the University of Pavia have identified a link between Amyotrophic Lateral Sclerosis (ALS) and the accumulation of DNA-RNA hybrids in the genome. The accumulation of these hybrids causes increased genomic damage and boosts genetic instability. This finding will make it possible to better understand the molecular basis of the disease, as well as to propose new solutions to curb it. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 13, 2021 Category: International Medicine & Public Health Source Type: news

BrainStorm Announces NurOwn(R) Expanded Access Program
NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria NEW YORK, Dec. 14, 2020 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASD... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2020 Category: Pharmaceuticals Source Type: news

Antiepileptic drug reduces motor neuron excitability in ALS
(Massachusetts General Hospital) The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital (MGH). In addition, the multi-site study involves the first clinical investigation of ALS using a drug identified through an induced pluripotent stem cell model. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 10, 2020 Category: International Medicine & Public Health Source Type: news

NIH researchers link cases of ALS and FTD to a Huntington's disease-associated mutation
(NIH/National Institute of Neurological Disorders and Stroke) A study led by researchers at the National Institutes of Health has made a surprising connection between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two disorders of the nervous system, and the genetic mutation normally understood to cause Huntington's disease. This large, international project, which included a collaboration between the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), opens a potentially new avenue for diagnosing and treating some individuals with FTD or ALS. (...
Source: EurekAlert! - Medicine and Health - December 4, 2020 Category: International Medicine & Public Health Source Type: news

Multi-center, multi-tracer PET studies harmonized to detect neuroinflammation in ALS
(Society of Nuclear Medicine and Molecular Imaging) A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease. Pooling data acquired from different scanners, different neuroinflammation positron emission tomography (PET) markers and different sites enhanced researchers' ability to detect neuroinflammation in ALS patients. This research was published in the November issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2020 Category: International Medicine & Public Health Source Type: news

ALS Ice Bucket Challenge Co-Founder Pat Quinn Dead At 37
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p16").init({"mcp":"cbs","width":"100%","height":"100%","video":"4895420","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p16","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","job...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 23, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Syndicated CBSN Boston ALS Ice Bucket Challenge Pat Quinn Pete Frates Source Type: news

BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Dr. Merit Cudkowicz and Dr. Ralph Kern presentation will be featured in Oral Presentation in the Clinical Trials Platform Session Clinical experience with outpatient NurOwn® administration will be presented in poster session NEW YORK, Nov. 23, 20... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, Amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 23, 2020 Category: Pharmaceuticals Source Type: news

Pat Quinn, Who Promoted A.L.S. Ice Bucket Challenge, Dies at 37
Mr. Quinn, who learned he had A.L.S. a month after he turned 30, was credited with helping to make the ice-bucket videos a viral sensation that raised $220 million worldwide. (Source: NYT Health)
Source: NYT Health - November 23, 2020 Category: Consumer Health News Authors: Concepci ón de León Tags: Amyotrophic Lateral Sclerosis Deaths (Obituaries) Ice Bucket Challenge ALS Assn Research Frates, Pete Philanthropy Quinn, Pat Source Type: news

BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Clinical trial did not meet statistical significance in primary efficacy endpoint NurOwn® showed a clinically meaningful treatment response compared to placebo in a pre-specified subgroup CSF biomarker analyses confirmed NurOwn resulted in a stat... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, Amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2020 Category: Pharmaceuticals Source Type: news

Chris Pendergast, Who Fought A.L.S. Mile After Mile, Dies at 71
Living for 27 years with Lou Gehrig ’s disease (and beating the odds), he started Ride for Life, an annual trek that has raised millions for A.L.S. research. (Source: NYT Health)
Source: NYT Health - October 29, 2020 Category: Consumer Health News Authors: Sam Roberts Tags: Pendergast, Chris (1949-2020) Deaths (Obituaries) Amyotrophic Lateral Sclerosis Lou Gehrig ' s Disease ALS Ride for Life (Nonprofit) Philanthropy Source Type: news

A wearable sensor to help ALS patients communicate
(Massachusetts Institute of Technology) MIT researchers have designed a skin-like device that can be attached to the face and measure small movements such as a twitch or a smile. With this approach, patients with amyotrophic lateral sclerosis (ALS) could communicate a variety of sentiments with small movements that are measured and interpreted by the device. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - October 22, 2020 Category: International Medicine & Public Health Source Type: news

Investigational Drug May Prolong Survival in Patients With ALS
TUESDAY, Oct. 20, 2020 -- Long-term survival analysis shows that patients with earlier initiation of sodium phenylbutyrate-taurursodiol (PB-TURSO) treatment for amyotrophic lateral sclerosis (ALS) have longer median overall survival, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 20, 2020 Category: Pharmaceuticals Source Type: news

New Drug Could Extend Life for People With ALS
FRIDAY, Oct. 16, 2020 -- An experimental drug combination lengthens survival for patients with amyotrophic lateral sclerosis (ALS), new research shows. A previous clinical trial found that the two-drug combo -- called AMX0035 -- slowed progression... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 16, 2020 Category: General Medicine Source Type: news

Drug May Extend A.L.S. Patients' Lives by Several Months, Study Finds
The two-drug combination invented by college students is one of many potential therapies being tested for this paralyzing fatal condition. (Source: NYT Health)
Source: NYT Health - October 16, 2020 Category: Consumer Health News Authors: Pam Belluck Tags: Amyotrophic Lateral Sclerosis Drugs (Pharmaceuticals) Clinical Trials Research Amylyx Pharmaceuticals Inc Food and Drug Administration ALS Assn Cohen, Joshua B Klee, Justin your-feed-healthcare Source Type: news

Investigational ALS drug prolongs patient survival in clinical trial
(Massachusetts General Hospital) An experimental medication that was recently shown to slow the progression of amyotrophic lateral sclerosis has now demonstrated the potential to also prolong patient survival. The findings come from a clinical trial conducted by investigators at the Sean M. Healey& AMG Center for ALS at Massachusetts General Hospital and Amylyx Pharmaceuticals, Inc., the company that manufactures the medication. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2020 Category: International Medicine & Public Health Source Type: news

Investigational drug stops toxic proteins tied to neurodegenerative diseases
(University of Pennsylvania School of Medicine) An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic. Results were published in Science Translational Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Drug Combo Slows Functional Decline in ALS Drug Combo Slows Functional Decline in ALS
A fixed-dose combination of sodium phenylbutyrate and taurursodiol slowed the rate of decline in physical function in patients with amyotrophic lateral sclerosis in the pivotal CENTAUR trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 3, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

New Drug Combo for ALS Slows Decline in Small Clinical Study
After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo. (Source: The Scientist)
Source: The Scientist - September 3, 2020 Category: Science Tags: News & Opinion Source Type: news

Sodium Phenylbutyrate-Taurursodiol Promising for ALS
THURSDAY, Sept. 3, 2020 -- For patients with amyotrophic lateral sclerosis (ALS), function declines more slowly through 24 weeks in those receiving sodium phenylbutyrate-taurursodiol versus placebo, according to a study published in the Sept. 3... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 3, 2020 Category: Pharmaceuticals Source Type: news

New Treatment for Lou Gehrig's Disease Shows Promise
A study of their therapy and clinical trials of other experimental treatments are offering glimmers of hope that paralysis from the disorder can be slowed. (Source: NYT Health)
Source: NYT Health - September 2, 2020 Category: Consumer Health News Authors: Pam Belluck Tags: Amyotrophic Lateral Sclerosis Clinical Trials Research Drugs (Pharmaceuticals) ALS Assn Food and Drug Administration National Institute of Neurological Disorders and Stroke New England Journal of Medicine Koroshetz, Walter J your-feed-he Source Type: news

Experimental Drug Shows Promise Against ALS
WEDNESDAY, Sept. 2, 2020 -- An experimental treatment may help slow the progression of the deadly brain disease amyotrophic lateral sclerosis (ALS), a new study finds. Researchers called the results a promising step in the fight against a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 2, 2020 Category: General Medicine Source Type: news

Scientists identify promising new ALS drug candidates
(University of Liverpool) Scientists have taken a significant step forward in the search to find effective new drug candidates for the treatment of Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2020 Category: International Medicine & Public Health Source Type: news

Clene Nanomedicine Raises Series D Financing of $42.5 Million
SALT LAKE CITY, Aug. 26, 2020 -- (Healthcare Sales & Marketing Network) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it has secured $42.5 million in a Series D financing. The round was led by SymBiosis II, ... Biopharmaceuticals, Neurology, Venture Capital Clene Nanomedicine, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2020 Category: Pharmaceuticals Source Type: news

RNA quality control system goes awry in frontotemporal lobar degeneration
(Osaka University) Researchers from Osaka University have uncovered that the RNA exosome is critical for the degradation of defective repeat RNA derived fromC9orf72 repeat expansions in patients withC9orf72-associated frontotemporal lobar degeneration and amyotrophic lateral sclerosis. The repeat RNA and resultant toxic proteins impaired RNA exosome function, which led to further accumulation of the defective RNA and protein. The findings outline a cycle that may accelerate neurodegeneration. Therapies disrupting the cycle may help treat the disorder. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 24, 2020 Category: Biology Source Type: news

Organoids and sequencing team up for ALS research
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) MDC researchers received a $150,000 pilot project grant from the Chan Zuckerberg Initiative's Neurodegeneration Challenge Network to investigate a defining feature of amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 20, 2020 Category: Biology Source Type: news

Blood Test Identifies People With ALS Blood Test Identifies People With ALS
A panel of eight micro RNA can identify patients with amyotrophic lateral sclerosis/motor neuron disease, researchers report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 28, 2020 Category: Pathology Tags: Neurology & Neurosurgery News Source Type: news

Decoding the Relationship Between Ageing and ALS Decoding the Relationship Between Ageing and ALS
This study aimed to elucidate the pathogenic mechanisms underlying amyotrophic lateral sclerosis. Might cell type-specific ageing be a key contributor to its development?Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 24, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

New Hope for ALS New Hope for ALS
Two studies using different approaches to suppress a gene linked to amyotrophic lateral sclerosis (ALS) may signal a new approach for treating the disorder.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 9, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Innovative ALS research fueled by $25 million from NIH
New initiative encourages research to transform treatment and prevention of amyotrophic lateral sclerosis, a devastating disease. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - July 6, 2020 Category: Environmental Health Source Type: news

Clearer understanding of disordered protein could aid ALS, Alzheimer's treatment search
(Lehigh University) A team led by Lehigh University biophysicist Jeetain Mittal and Brown University structural biologist Nicolas Fawzi has been awarded a $3.3 million NIH grant to study the atomistic structure and mechanisms of TAR DNA-binding protein 43 (TDP-43). Neuronal deposits of this protein are found in people living with Alzheimer's and related dementias, as well as people diagnosed with amyotrophic lateral sclerosis (ALS). The research will also investigate interactions with several promising therapeutic targets. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2020 Category: International Medicine & Public Health Source Type: news

Verge Genomics to advance its inhibitors of PIKfyve for the treatment...
Verge Genomics announced this week at BIO International its lead program for amyotrophic lateral sclerosis (ALS) is the endosomal lipid kinase, PIKfyve, with plans to enter clinical trials next year....(PRWeb June 11, 2020)Read the full story at https://www.prweb.com/releases/verge_genomics_to_advance_its_inhibitors_of_pikfyve_for_the_treatment_of_als_and_covid_19/prweb17178507.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 11, 2020 Category: Pharmaceuticals Source Type: news

Researchers identify new genetic defect linked to ALS
(University of Maryland School of Medicine) Researchers at the University of Maryland School of Medicine (UMSOM) have identified how certain gene mutations cause amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The pathway identified by the researchers may also be responsible for a certain form of dementia related to ALS. The finding could offer potential new approaches for treating this devastating condition. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2020 Category: International Medicine & Public Health Source Type: news

Researchers conduct metabolite analysis of ALS patient blood plasma
(North Carolina State University) High-throughput analysis of blood plasma could aid in identification of diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis (ALS). The work sheds further light on a pathway involved in disease progression and appears to rule out an environmental neurotoxin as playing a role in ALS. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 29, 2020 Category: Biology Source Type: news

Genetic doppelgaengers: Emory research provides insight into two neurological puzzles
(Emory Health Sciences) Insight into the pathological mechanisms behind two devastating neurodegenerative diseases: the most common inherited form of amyotrophic lateral sclerosis/ frontotemporal dementia (ALS/FTD) and spinocerebellar ataxia type 36 (SCA36). Expanded repeats lead to peptide gobbledygook in both, but with critical differences. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2020 Category: International Medicine & Public Health Source Type: news

Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
VANCOUVER, British Columbia, April 30, 2020 -- (Healthcare Sales & Marketing Network) -- Alpha Cognition Inc. (ACI) today announced that in a pre-Investigational New Drug (Pre-IND) meeting, the U.S. Food and Drug Administration (USFDA) agreed upon a clini... Biopharmaceuticals, Neurology, FDA Alpha Cognition, Alzheimer's Disease, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2020 Category: Pharmaceuticals Source Type: news

Researchers delay onset of amyotrophic lateral sclerosis (ALS) in laboratory models
(University of Toronto) Scientists have delayed the onset of amyotrophic lateral sclerosis (ALS) in laboratory models, leaving them cautiously optimistic that the result, combined with other clinical advances, points to a potential treatment for ALS in humans. The researchers targeted neurons in the brain's motor cortex with an engineered protein that prevented their degeneration and delayed the onset of symptoms such as hardening of the neuron's myelin sheath, weight loss and a deterioration in motor skills. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 20, 2020 Category: International Medicine & Public Health Source Type: news

Caring for Relatives With ALS Almost a Full-Time Job for Youth: Study
FRIDAY, March 27, 2020 -- Kids and teens spend as much as five hours a day helping care for relatives with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a new study finds. Although the young people often help with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 27, 2020 Category: General Medicine Source Type: news

Scientists identify gene that first slows, then accelerates, progression of ALS in mice
(The Zuckerman Institute at Columbia University) Columbia scientists have provided new insights into how mutations in a gene called TBK1 cause amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that robs patients of movement, speech and ultimately, their lives. The researchers found that ALS-associated mutations in TBK1 can have both positive and negative effects on the progression of disease in mice genetically modified to have ALS-like symptoms. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 27, 2020 Category: Biology Source Type: news